ViroGates A/S (VIRO.CO)

7.14 -0.24 (-3.25%) At close: 12:58PM CEST

ViroGates A/S

BanevAenget 13
Birkerød 3460
Denmark
45 21 13 13 36
https://www.virogates.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jakob Knudsen	Chief Executive Officer	1.6M	N/A	1968
Dr. Jesper Eugen-Olsen	Co-Founder & Chief Scientific Officer	N/A	N/A	1963
Ms. Josephine Baum Jorgensen	Chief Financial Officer	N/A	N/A	1991
Ms. May Britt Dyvelkov	Vice President of Accounting	N/A	N/A	1960
Mr. Thomas Krarup	Vice President of Global Sales & Marketing	N/A	N/A	1963
David Stig Poulsen	Head of Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company' products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood. The company was founded in 2000 and is headquartered in Birkerød, Denmark.

Corporate governance

ViroGates A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.